Form 4: Harvard Apparatus Regenerative Technology Director Li Ting Receives Significant Equity Grants

Director Li Ting of Harvard Apparatus Regenerative Technology, Inc. was granted 33,817 stock options with a $1.6 exercise price, comprising an annual equity grant and an award in lieu of cash compensation.

Summary

• Director Li Ting of Harvard Apparatus Regenerative Technology, Inc. (HRGN) was granted a total of 33,817 stock options on June 27, 2025, each with an exercise price of $1.6.
• One grant of 18,590 stock options represents the annual equity compensation for Li Ting as a non-employee director. These options will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026, and June 27, 2026.
• A second grant of 15,227 stock options was awarded to Li Ting in lieu of cash compensation for their role as a non-employee director. These options will vest in four equal installments on the grant date (June 27, 2025), June 30, 2025, September 30, 2025, and December 31, 2025.
• All granted stock options have an expiration date of June 27, 2035.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates standard compensation practices, aligns director interests with shareholders, and potentially conserves cash for the company. It's a routine transaction with no negative implications.

Positives

• The grants align the interests of Director Li Ting with those of shareholders, as the value of the options increases with the company's stock price.
• The use of equity grants as part of compensation, including in lieu of cash, can help conserve the company's cash reserves.

Future Outlook

The document details future vesting schedules for stock options, indicating a continued alignment of director compensation with future company performance over the vesting periods.

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, particularly in biotechnology and medical device sectors like Harvard Apparatus Regenerative Technology, Inc., to attract and retain talent, align interests, and conserve cash.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors is standard across publicly traded companies, including those in the biotechnology and medical device sectors.
• The vesting schedules, particularly the multi-year vesting for the annual grant, are typical for long-term incentive plans designed to retain directors and align their interests with sustained company performance.
• Granting equity in lieu of cash compensation is also a common strategy, especially for smaller or growth-oriented companies, to manage cash flow while still providing competitive compensation.

Related Party Transactions

• The stock option grants to Director Li Ting represent compensation for services rendered as a non-employee director, which is a common form of related party transaction in corporate governance.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value. The issuance of new shares upon option exercise could lead to minor dilution, but this is typical for equity compensation plans.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: The use of equity in lieu of cash compensation for a director could indirectly benefit creditors by preserving cash on the balance sheet, though the impact is likely minimal.

Next Steps

• Vesting of 18,590 annual equity grant stock options in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026, and June 27, 2026.
• Vesting of 15,227 stock options granted in lieu of cash compensation in four equal installments on June 27, 2025 (grant date), June 30, 2025, September 30, 2025, and December 31, 2025.
• Potential exercise of stock options by Director Li Ting at any point between their vesting dates and the expiration date of June 27, 2035.

Key Dates

Keywords

Harvard Apparatus Regenerative Technology, HRGN, Li Ting, Stock Options, Equity Grant, Director Compensation, SEC Form 4, Insider Transaction, Non-Employee Director